New needle-free nasal vaccine shows promise for COVID-19
New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mBio, an open access journal of the American Society for Microbiology.
In recent years, the Food and Drug Administration authorized mRNA- and adenovirus-based SARS-CoV-2 vaccines.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
More News: Adenoviruses | Covid Vaccine | COVID-19 | Food and Drug Administration (FDA) | Microbiology | Pharmaceuticals | SARS | Vaccines